TrialClinical epigenetics2025

Phase II study of dual epigenetic targeting with chidamide and azacitidine in patients with high-risk acute myeloid leukemia after allo-HSCT.

Ya-Xue Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.